Dexamethasone/netilmicin - SIFI

Drug Profile

Dexamethasone/netilmicin - SIFI

Alternative Names: Dexamethasone/netilmicin; Netildex; Netilmicin/dexamethasone

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator SIFI
  • Class Anti-infectives; Anti-inflammatories; Eye disorder therapies
  • Mechanism of Action Arachidonic acid inhibitors; Bacterial protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation

Most Recent Events

  • 22 Nov 2016 SIFI and Sintesi Research Srl plan a phase III trial for Ocular inflammation associated with cataract extraction in Italy, Germany and Romania (Ophthalmic, Gel) (NCT02973880)
  • 15 Sep 2016 Chemical structure information added
  • 02 Aug 2016 SIFI and Knight Pharmaceuticals entered into an agreement for the regulatory and commercial activities in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top